ArticleJournal of cardiothoracic surgery2025
Potential auxiliary diagnostic role of pentraxin 3 in plasma and bronchoalveolar lavage fluid for pulmonary tuberculosis.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to assess the auxiliary diagnostic efficacy of Pentraxin 3 (PTX3) as a biomarker for pulmonary tuberculosis (TB) by analyzing its levels in plasma and bronchoalveolar lavage fluid (BALF) in TB patients. Given the limitations of current TB diagnostic methods, the investigation also sought to evaluate the possible auxiliary help of PTX3 in distinguishing TB from other pulmonary conditions.
methodsThe bioinformatic analysis utilized the Gene Expression Omnibus (GEO) dataset (GSE34608), including peripheral blood samples from individuals with TB, sarcoidosis, and healthy controls. Clinical specimens were obtained from hospitalized patients between January 2020 and March 2022, comprising 126 peripheral blood samples and 68 BALF samples. PTX3 levels were measured via enzyme-linked immunosorbent assays (ELISA), with subsequent statistical analyses conducted to assess the auxiliary diagnostic efficacy of PTX3 through ROC curve analysis.
resultsThe analysis of the GEO dataset revealed a notable increase in PTX3 levels in the peripheral blood of TB patients compared to controls, with an area under the curve (AUC) of 0.889. However, no significant differences in plasma PTX3 levels were observed among TB, community-acquired pneumonia (CAP), and lung cancer patients in clinical samples (AUC: 0.472). Conversely, PTX3 levels in BALF were significantly elevated in TB patients compared to individuals with CAP and lung cancer (P < 0.001), with an AUC of 0.806, along with a sensitivity of 0.800 and specificity of 0.810, suggesting its potential auxiliary diagnostic utility.
conclusionPlasma PTX3 levels have limited diagnostic utility in distinguishing tuberculosis from other pulmonary conditions, whereas BALF PTX3 levels exhibit more possible auxiliary diagnosis ability as an auxiliary diagnostic indicator, offering a localized assessment of lung inflammation. BALF PTX3 could be a helpful adjunct in diagnosing TB, particularly in cases where conventional sputum-based tests are inconclusive. Further research is needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.